Soligenix Inc. extended its collaboration with IDT Biologika for the manufacture of RiVax, Soligenix's proprietary recombinant subunit vaccine developed to protect against exposure to ricin toxin.

Soligenix will advance the formulation and filling processes and will continue development and validation of analytical methods established at IDT to move the program toward a commercially viable scalable technology for the RiVax vaccine.

Soligenix has been developing RiVax, in conjunction with its heat stabilization technology, ThermoVax, as a heat-stable biodefense vaccine. The RiVax project is supported with National Institute of Allergy and Infectious Diseases funding of up to $24.7 million.